Glenmede Trust’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Glenmede Trust’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-185	Closed	–	–	2741
2016 Q1	$0	Buy	+185	New	+$1.13K	﹤0.01%	2740

Other funds holding INFI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust's INFI Position: Q2 2016 in Review

Glenmede Trust sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2016, closing a stake of 185 shares.

Glenmede Trust first reported a position in INFI in Q1 2016 and held it in 1 quarter. The position peaked at $0 in Q1 2016. 107 funds tracked by Wall St. Rank hold INFI as of Q2 2016.

Glenmede Trust reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Glenmede Trust sold 185 Infinity Pharmaceuticals, Inc. shares in Q2 2016.
Glenmede Trust first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
Glenmede Trust's Infinity Pharmaceuticals, Inc. position peaked at $0 in Q1 2016.
107 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2016.

Based on Glenmede Trust's 13F filing for Q2 2016, filed 5 Aug 2016.